Has tucatinib been launched in the country? Can it still be used?

Tucatinib (trade name: Tukysa) has not yet been officially launched in China. Tucatinib was first approved by the U.S. FDA on April 17, 2020, for the treatment of HER2-positive breast cancer. It was subsequently approved in other countries, including Switzerland.

Although tucatinib has been on the market for many years abroad and has achieved remarkable results in the treatment of HER2 positive breast cancer, the drug has not yet been approved for marketing in China. This means that domestic patients cannot purchase tucatinib directly from formal channels in China.

Although tucatinib is not available in China, some patients may try to purchase it through hospital pharmacies, online pharmacies or regular overseas purchasing agents. However, these channels need to be selected carefully to ensure that reliable quality drugs are purchased.

Since the versions and prices of tucatinib vary in different countries, patients should choose an appropriate purchase method based on their own needs and financial status. At the same time, there are legality and safety issues with overseas purchasing agents and other channels, and patients must bear their own risks.

Currently, tucatinib has been applied for listing in China, but the specific launch time has not yet been determined. It is expected that tucatinib may be approved for marketing in 2025. However, this time point may be affected by a variety of factors, including the drug approval process, market demand, etc.

Once tucatinib is launched in China, it will provide more treatment options for HER2 positive breast cancer patients. As an oral, highly selective HER2 small molecule targeted drug, tucatinib has unique pharmacological properties and therapeutic effects, which can significantly reduce the patient's risk of death.

References:

https://go.drugbank.com/drugs/DB11652